Amneal Pharmaceuticals (AMRX) Gross Profit (2017 - 2026)
Amneal Pharmaceuticals (AMRX) posted quarterly Gross Profit of $320.1 million for Q1 2026, up 25.1% year-over-year from $255.9 million in Q1 2025, and up 7.71% quarter-over-quarter from $297.2 million in Q4 2025.
Amneal Pharmaceuticals (AMRX) Gross Profit (2017 - 2026) Analysis & Trends
Amneal Pharmaceuticals' Gross Profit history runs 10 years deep, the most recent figure standing at $320.1 million for Q1 2026.
- In Q1 2026, Gross Profit rose 25.1% year-over-year to $320.1 million; the TTM figure through Mar 2026 stood at $1.2 billion (up 13.41% YoY), while the FY2025 annual figure was $1.1 billion, up 9.1% from the prior year.
- Gross Profit for Q1 2026 stood at $320.1 million, up from $297.2 million in the prior quarter.
- The five-year high for Gross Profit was $320.1 million in Q1 2026, with the low at $174.6 million in Q1 2022.
- The 5-year median for Gross Profit is $238.1 million (2024), against an average of $238.8 million.
- The sharpest annual moves came in 2023 and 2024: Gross Profit dropped 11.87% in 2023, then surged 38.48% in 2024.
- Amneal Pharmaceuticals' Gross Profit stood at $215.4 million in 2022, then fell by 11.87% to $189.8 million in 2023, then surged by 38.48% to $262.9 million in 2024, then grew by 13.05% to $297.2 million in 2025, then climbed by 7.71% to $320.1 million in 2026.
- Business Quant data shows AMRX's Gross Profit at $320.1 million in Q1 2026, $297.2 million in Q4 2025, and $274.0 million in Q3 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|